Glaukos Corp. (GKOS) News Headlines

▮ More

Date

Headline

2/27/2023 7:03:07 AM Glaukos Submits NDA To U.S. FDA For IDose TR

9/7/2022 7:22:24 AM Glaukos Reports Positive Topline Outcomes For Both Phase 3 Pivotal Trials Of IDose TR

9/7/2022 7:03:15 AM Glaukos Announces Positive Topline Outcomes For Both Phase 3 Pivotal Trials Of IDose TR

3/14/2022 7:10:07 AM Glaukos Begins Phase 2 Corneal Health Clinical Program For Third-Generation ILink Therapy

2/11/2022 7:59:29 AM Pre-market Movers: MODD, BWMX, BRLT, BL, UVE …

11/3/2021 10:22:57 AM Why Is Glaukos Surging?

11/3/2021 6:39:36 AM Pre-market Movers: BBBY, RRD, GKOS, TMBR, IRTC…

9/15/2021 7:07:42 AM Glaukos Announces Settlement Of Patent Litigation With Ivantis

9/3/2021 7:17:38 AM Glaukos Files Supplemental Pre-market Approval Application For IStent Infinite

9/3/2021 7:05:44 AM Glaukos Submits Supplemental Pre-market Approval Application To FDA For IStent Infinite Trabecular Micro-Bypass System

7/20/2021 10:00:09 AM Glaukos Downtick Continues; Shares Slip 15%

7/14/2021 10:04:25 AM Glaukos Shares Tank Nearly 25% Hurt Largely By Latest Proposed Physician Fee Schedule

7/14/2021 2:14:49 AM Glaukos Says Disappointed With CMS' Proposed 2022 Physician Fees For Category I Codes

6/10/2021 7:31:26 AM Glaukos Completes Patient Enrollment And Randomization In NDA Phase 3 Clinical Trials For IDose(r) TR

6/8/2021 7:22:33 AM Glaukos Announces Australia's TGA Regulatory Approval For PRESERFLO MicroShunt

3/1/2021 4:24:05 PM Glaukos Appoints Denice Torres And Leana Wen To Its Board Of Directors

1/13/2021 7:15:42 AM Glaukos Expects Q4 Net Sales To Be About $73 Mln

1/13/2021 7:12:50 AM Glaukos Says IDose TR Demonstrates Sustained IOP Reduction And Favorable Safety Profile Over 24 Months In Phase 2b Study

3/23/2018 7:58:30 AM William Blair Reiterates Glaukos Corp. (GKOS) At Outperform

3/1/2018 9:05:09 AM William Blair Reiterates Glaukos Corp. (GKOS) At Outperform

Older Articles